Comparison

Abiraterone European Partner

Item no. S1123-5000
Manufacturer Selleckchem
CASRN 154229-19-3
Amount 5 g
Quantity options 10 mg 100 mg 1 g 10 g 200 mg 25 mg 5 mg 50 mg 5 g
Category
Type Inhibitors
Specific against other
Smiles CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias CB-7598
Similar products Abiraterone
Available
Storage Conditions
2 years -80 in solvent
Molecular Weight
349, 51
Administration
Administered via s.c.
Animal Models
LAPC-4 xenograft mice
Cell lines
LNCaP and VCaP cells
Clinical Trials
Abiraterone acetate plus prednisone has entered in a phase II clinical trial in the treatment of prostate cancer.
Concentrations
0.1-5 uM
Dosages
0.15 mmol/kg
Formulation
0.3% hydroxypropyl cellulose
IC50
2 nM [1], 2 nM [1], 2 nM [1], 2 nM [1], 2 nM [1], 2 nM [1]
In vitro
Abiraterone binds and inhibits wild-type and mutant androgen receptor (AR). Abiraterone inhibits in vitro proliferation and androgen receptor-regulated gene expression of androgen receptor-positive prostate cancer cells, which could be explained by androgen receptor antagonism in addition to inhibition of steroidogenesis. In fact, activation of mutant androgen receptor by eplerenone is inhibited by greater concentrations of Abiraterone. Abiraterone displaces ligand from both WT-AR and T877A with EC50 of 13.4 uM and 7.9 uM, respectively. [2]Abiraterone inhibits lyase activity with an IC50 of 5.8 nM in rat testis microsomes. Abiraterone acetate significantly inhibits T secretion ( 48%) and in turn increased LH concentration (192%).[3]
In vivo
Abiraterone inhibits CYP17 with an IC50 of 72 nM, in human testicular microsomes. [4] Abiraterone fails to significantly reduce the size of any of the organs. [5] Abiraterone reduces the testosterone levels strongly, almost reaching the level of the orchiectomy control. The testosterone levels are reduced by Abiraterone for more than 95% compared to the control group. [6]
Incubation Time
24 hours or 96 hours
Kinase Assay
[3], C17, 20-lyase activity assay, Microsomes are diluted to a final protein concentration of 50 ug/mL in the reaction mixture which contained 0.25 M sucrose, 20 mM Tris–HCl (pH 7.4), 10 mM G6P and 1.2 IU/mL G6PDH. After equilibration at 37 C for 10 minutes, the reaction is initiated by addition of betaNADP to obtain a final concentration of 0.6 mM. Prior to the distribution of 600 uL of the reaction mixture in each tube, Abiraterone is evaporated to dryness under a stream of nitrogen and then are incubated at 37 C for 10 minutes. After incubation with Abiraterone, 500 uL of the reaction mixture is transferred to tubes containing 1 uM of the enzyme substrate, 17OHP. After a further 10 minutes incubation, tubes are placed on ice and the reaction is stopped by addition of 0.1 ml NaOH 1N. Tubes are deep-frozen and stored at 20 C until assayed for delta4A levels. A delta4A RIA is developed and automated on a microplate format using a specific antibody against delta4A. The separation of free and bound antigen achieved with a dextran-coated charcoal suspension. After centrifugation, aliquots of the clear supernatant are counted in duplicates in a 1450 MicrobetaPlus liquid scintillation counter. The delta4A concentrations of unknown samples are determined from the standard curve. The detection limit is 0.5 ng/mL and the within and between assay coefficients of variation are 10.7 and 17.6%, respectively at an assay value of 13 ng/mL. The rate of enzymatic reaction is expressed as pmol of delta4A formed per 10 minutes and per mg of protein. The value of maximum activity without inhibitor (control) is set at 100%. The IC50 values are calculated using non-linear analysis from the plot of enzyme activity (%) against log of inhibitor concentration.
Method
LNCaP and VCaP cells are seeded in 96-well plates and grown in CSS-supplemented phenol red-free or FBS-supplemented media for 7 days. Cells are treated with Abiraterone at 24 hours and 96 hours after plating and cell viability is determined on day 7 by adding CellTiter Glo and measuring luminescence.
Solubility (25C)
DMSO 0.33 mg/mL, Water <1 mg/mL, Ethanol <1 mg/mL
Information
Abiraterone is a potent CYP17 inhibitor with IC50 of 2 nM in a cell-free assay. Abiraterone (CB-7598) is an androgen biosynthesis inhibitor.
Features
Abiraterone has been approved for the treatment of docetaxel-treated castration-resistant prostate cancer (CRPC).

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 5 g
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?